ETF甄选 | 三大指数震荡走弱，卫星、港股消费、创新药等相关ETF表现亮眼

Group 1: Market Overview - The market experienced a decline with major indices closing lower: Shanghai Composite Index down 0.70%, Shenzhen Component Index down 1.27%, and ChiNext Index down 1.41% [1] - Sectors showing gains included superconductors, controllable nuclear fusion, and non-metallic materials, while real estate services, real estate development, and commercial retail sectors faced declines [1] - Main capital inflows were observed in controllable nuclear fusion, superconductors, and wind power equipment industries [1] Group 2: Commercial Aerospace Investment - Guojin Securities noted that China is at a pivotal moment similar to SpaceX's network formation phase from 2018 to 2020, with a shift from custom satellite manufacturing to mass production [1] - The upcoming launch of the Wenchang Super Satellite Factory and SpaceX's planned IPO next year indicate a significant acceleration in global commercial aerospace investment and industrialization [1] - Key investment areas include commercial aerospace, low-altitude economy, and military trade, with advancements in reusable rocket technology expected to lower launch costs and accelerate satellite constellation deployment [1] Group 3: Consumer Market Trends - Multiple regions have introduced policies to boost consumption, with Jiangsu's "14th Five-Year Plan" focusing on expanding and upgrading consumer goods, particularly in automobiles and home appliances [2] - Haitong Securities highlighted a structural growth opportunity in the consumer sector driven by technological advancements and the emergence of new consumption trends, such as trendy toys and beauty products [2] - The outlook for 2026 suggests that ongoing consumption policies will stimulate supply and demand, leading to a steady recovery in domestic demand [2] Group 4: Innovation in Pharmaceuticals - Aijian Securities expressed optimism about the trend of Chinese innovative drugs entering international markets, noting that A/H innovative drug companies' valuations have returned to reasonable levels after adjustments [2] - The focus for 2026 will be on investment opportunities in key areas such as antibody-drug conjugates (ADC), bispecific antibodies, small nucleic acids, and weight-loss drugs [2] - CITIC Securities indicated that innovative drugs are expected to be a major upward trend in the cross-year market, supported by China's pharmaceutical industry's transition to "innovation realization + global layout" [3]